GOLDMAN SACHS GROUP INC - KARYOPHARM THERAPEUTICS INC ownership

KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 151 filers reported holding KARYOPHARM THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of KARYOPHARM THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,566,163
-11.6%
1,915,047
+18.1%
0.00%0.0%
Q2 2023$2,901,624
-49.2%
1,621,019
+10.3%
0.00%0.0%
Q1 2023$5,714,982
+59.1%
1,469,147
+39.0%
0.00%0.0%
Q4 2022$3,592,552
-51.4%
1,056,633
-22.0%
0.00%
-50.0%
Q3 2022$7,399,000
+13.4%
1,355,176
-6.3%
0.00%
+100.0%
Q2 2022$6,523,000
-1.5%
1,446,402
+60.9%
0.00%0.0%
Q1 2022$6,625,000
+0.2%
898,906
-12.6%
0.00%0.0%
Q4 2021$6,615,000
+15.3%
1,028,882
+4.4%
0.00%0.0%
Q3 2021$5,735,000
-44.7%
985,382
-2.0%
0.00%
-50.0%
Q2 2021$10,379,000
-18.6%
1,005,721
-17.0%
0.00%
-33.3%
Q1 2021$12,750,000
-21.9%
1,211,971
+14.9%
0.00%
-25.0%
Q4 2020$16,328,000
+29.3%
1,054,762
+22.0%
0.00%0.0%
Q3 2020$12,624,000
-66.7%
864,678
-56.8%
0.00%
-66.7%
Q2 2020$37,881,000
+105.6%
2,000,078
+108.5%
0.01%
+100.0%
Q1 2020$18,427,000
+72.9%
959,251
+72.5%
0.01%
+100.0%
Q4 2019$10,660,000
+92.3%
556,056
-3.5%
0.00%
+50.0%
Q3 2019$5,542,000
+458.1%
576,123
+247.6%
0.00%
Q2 2019$993,000
+4.0%
165,763
+1.3%
0.00%
Q1 2019$955,000
-36.7%
163,566
+1.6%
0.00%
Q4 2018$1,508,000
-68.3%
160,921
-42.3%
0.00%
-100.0%
Q3 2018$4,750,000
-45.0%
278,877
-45.1%
0.00%
-50.0%
Q2 2018$8,631,000
+476.6%
507,986
+355.4%
0.00%
Q1 2018$1,497,000
+99.6%
111,545
+42.8%
0.00%
Q4 2017$750,000
-15.4%
78,107
-3.3%
0.00%
Q3 2017$887,000
+108.2%
80,747
+71.7%
0.00%
Q2 2017$426,000
-58.4%
47,033
-41.0%
0.00%
Q1 2017$1,024,000
+7.1%
79,724
-21.6%
0.00%
Q4 2016$956,000
+102.5%
101,702
+109.6%
0.00%
Q3 2016$472,000
+70.4%
48,514
+17.6%
0.00%
Q2 2016$277,000
+188.5%
41,264
+284.0%
0.00%
Q1 2016$96,000
-97.9%
10,747
-97.6%
0.00%
-100.0%
Q3 2015$4,642,000
-8.2%
440,808
+137.1%
0.00%
-66.7%
Q2 2015$5,059,000
+8.3%
185,882
+21.9%
0.00%
+200.0%
Q1 2015$4,670,000
+185.5%
152,541
+249.0%
0.00%0.0%
Q4 2014$1,636,000
+389.8%
43,704
+357.4%
0.00%
Q3 2014$334,000
-31.6%
9,555
-8.8%
0.00%
Q2 2014$488,000
-26.4%
10,481
-51.1%
0.00%
Q1 2014$663,00021,4550.00%
Other shareholders
KARYOPHARM THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
AIGH Capital Management LLC 1,773,474$2,376,4561.12%
AlphaCentric Advisors LLC 1,125,000$1,507,5000.86%
Tejara Capital Ltd 1,077,388$1,443,7000.82%
Palo Alto Investors LP 5,675,876$7,605,6740.72%
Birchview Capital, LP 571,832$766,2550.65%
Altium Capital Management LP 740,000$991,6000.52%
Avidity Partners Management LP 8,298,570$11,120,0840.45%
Worth Venture Partners, LLC 445,981$597,6150.36%
SILVERARC CAPITAL MANAGEMENT, LLC 561,955$753,0200.23%
DAFNA Capital Management LLC 192,678$258,1890.08%
View complete list of KARYOPHARM THERAPEUTICS INC shareholders